breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - Æxlishemjandi lyf - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
risperdal consta stungulyfsstofn og leysir, forðadreifa 50 mg
janssen-cilag ab - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 50 mg
risperdal consta stungulyfsstofn og leysir, forðadreifa 37,5 mg
janssen-cilag ab - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 37,5 mg
risperdal consta stungulyfsstofn og leysir, forðadreifa 25 mg
janssen-cilag ab - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 25 mg
grazax frostþurrkuð tungurótartafla 75.000 sq-t
alk-abelló a/s - phleum pratense - frostþurrkuð tungurótartafla - 75.000 sq-t
risperidone teva gmbh stungulyfsstofn og leysir, forðadreifa 50 mg
teva gmbh - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 50 mg
risperidone teva gmbh stungulyfsstofn og leysir, forðadreifa 25 mg
teva gmbh - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 25 mg
risperidone teva gmbh stungulyfsstofn og leysir, forðadreifa 37,5 mg
teva gmbh - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 37,5 mg
tafil tafla 0,25 mg
upjohn eesv - alprazolamum inn - tafla - 0,25 mg
tafil tafla 0,5 mg
upjohn eesv - alprazolamum inn - tafla - 0,5 mg